vimarsana.com

14.02.2024 - Phase 1b portion of the study expected to be completed within six monthsOCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus ...

Related Keywords

Jenene Thomas ,Twitter ,Exchange Commission ,Facebook ,Linkedin ,Immunotech Inc ,Pancreato Biliary Surgeon ,Response Evaluation ,Private Securities Litigation Reform Act ,Investor Contact ,Aim Immunotech Chart ,Im Immunotech Kurs ,Im Immunotech Aktie ,

© 2025 Vimarsana

vimarsana.com © 2020. All Rights Reserved.